The XALute clinical trial is a Phase 3 research study evaluating xaluritamig, an investigational immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). This trial is studying whether xaluritamig can help the immune system more effectively target and fight advanced prostate cancer compared with standard treatment options, including cabazitaxel.

The discussion features leading prostate cancer experts:

• Dr. Keith Crawford, Director of Clinical Trials and Patient Education, Prostate Health Education Network (PHEN)

• Dr. David Einstein, Academic Medical Oncologist and Clinical Trial Investigator, Beth Israel Deaconess Medical Center

Topics include how xaluritamig works, what the XALute clinical trial is testing, eligibility requirements, and how patients and caregivers can explore prostate cancer clinical trials using trusted resources like PHENTrials.com.

This video provides clear, reliable information to help patients with advanced prostate cancer better understand emerging treatment options and clinical trial opportunities.

To learn more about prostate cancer clinical trials or see if you may qualify, visit PHENTrials.com.